Industry news that matters to you.  Learn more

Sysmex Inostics Announces Agreement With IndivuTest to Offer Sysmex Inostics Blood Based Mutation Testing in Germany, Austria and Switzerland

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that they have signed an exclusive distributor agreement with IndivuTest GmbH, and its parent company Indivumed GmbH, a cancer research company focused on the development of individualized cancer diagnostics and therapies. This collaboration will offer Sysmex Inostics OncoBEAM™ CLIA laboratory services throughout Germany, Austria and Switzerland. IndivuTest will be responsible for commercial and sample logistics, with all testing being performed in the Sysmex Inostics’ CLIA laboratory in Baltimore, Maryland.

Sysmex Inostics and Merck Serono Announce First RAS Testing Center Implementing Sysmex Inostics’ Blood-based OncoBEAM Testing in Spain: Important Milestone for mCRC Patients

Sysmex Inostics, a subsidiary of Sysmex Corporation, recently announced the first RAS biomarker testing site offering their (Sysmex Inostics) blood-based OncoBEAM™ tests in Spain. Aside from Sysmex Inostics’ US-based CLIA certified laboratory, the Vall d’Hebron Institute of Oncology located in Barcelona, Spain, will be the first of numerous medical centers globally to use OncoBEAM™ assays for patients with metastatic colorectal cancers (mCRC) once CE Mark is received. This marks an important milestone in Sysmex Inostics’ collaboration with Merck’s biopharmaceutical business, Merck Serono, for the development and commercialization of a RAS biomarker testing kit for patients with mCRC, which was signed at a ceremony coinciding with the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, U.S in June 2014.